Trials that use: Exact / Clopper-Pearson binomial
New to this method? Read the tutorial →
1,265 results
- Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML): Complete Statistical AnalysisIndependent statistical analysis of Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00379197).
- Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Phase II Study of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M Neuroblastoma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M Neuroblastoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum-Based Doublet Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum-Based Doublet Chemotherapy: primary endpoint results,…
- Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Phase l/II Study of Ruxolitinib for Acute Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Phase l/II Study of Ruxolitinib for Acute Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01251965).
- Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02217709).
- PHranceSCaIndependent statistical analysis of A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer: primary endpoint…
- Physiologic Pacing Registry: Complete Statistical AnalysisIndependent statistical analysis of Physiologic Pacing Registry: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03719040).
- Physiological Flow of Liquids in Healthy Swallowing: Complete Statistical AnalysisIndependent statistical analysis of Physiological Flow of Liquids in Healthy Swallowing: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04114617).
- Physiological Flow of Liquids Used in Dysphagia Management (Neuro): Complete Statistical AnalysisIndependent statistical analysis of Physiological Flow of Liquids Used in Dysphagia Management (Neuro): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03192358).
- PictureRx: Improving Medication Safety in Health Disparity Populations: Complete Statistical AnalysisIndependent statistical analysis of PictureRx: Improving Medication Safety in Health Disparity Populations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02289469).
- PII S3i CAPIndependent statistical analysis of PARTNER II Trial: S3iCAP: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02687035).
- PiiitchIndependent statistical analysis of Feasibility of Cocooning Immunization Strategy With Influenza Vaccine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00570037).
- Pilot Project of Health Promotion for People With Diabetes: Complete Statistical AnalysisIndependent statistical analysis of Pilot Project of Health Promotion for People With Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00970294).
- Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Pilot Study of ACTH in the Treatment of Immunoglobulin A (IgA) Nephropathy at High Risk of Progression: Complete Statistical AnalysisIndependent statistical analysis of Pilot Study of ACTH in the Treatment of Immunoglobulin A (IgA) Nephropathy at High Risk of Progression: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Pilot Study of Adding Raltegravir (MK-0518) to Antiretroviral Therapy in Patients With Low Level Viremia: Complete Statistical AnalysisIndependent statistical analysis of Pilot Study of Adding Raltegravir (MK-0518) to Antiretroviral Therapy in Patients With Low Level Viremia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Pilot Study PBSCT With TCRab Depletion For Hemoglobinopathies: Complete Statistical AnalysisIndependent statistical analysis of Pilot Study PBSCT With TCRab Depletion For Hemoglobinopathies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04523376).
- Piloting ‘mPal,’ a Multilevel Strategy for Palliative Care Implementation: Complete Statistical AnalysisIndependent statistical analysis of Piloting 'mPal,' a Multilevel Strategy for Palliative Care Implementation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05270395).
- PilotNR-LVADIndependent statistical analysis of Nicotinamide Riboside in LVAD Recipients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03727646).
- Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement: Complete Statistical AnalysisIndependent statistical analysis of Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Pioglitazone Special Drug Use Surveillance “Metabolic Syndrome in Patients With Type 2 Diabetes Mellitus”: Complete Statistical AnalysisIndependent statistical analysis of Pioglitazone Special Drug Use Surveillance "Metabolic Syndrome in Patients With Type 2 Diabetes Mellitus": primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-refractory Low-grade or Transformed Low-grade B-cell Non-Hodgkin’s Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-refractory Low-grade or Transformed Low-grade B-cell Non-Hodgkin's Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- PK Profile and Preliminary Efficacy of TNP-2092 Capsules in Liver Cirrhosis Patients With Hyperammonemia: Complete Statistical AnalysisIndependent statistical analysis of PK Profile and Preliminary Efficacy of TNP-2092 Capsules in Liver Cirrhosis Patients With Hyperammonemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT): Complete Statistical AnalysisIndependent statistical analysis of Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Plasmodium Vivax Efficacy Trial in Cruzeiro do Sul, Acre, Brazil: Complete Statistical AnalysisIndependent statistical analysis of Plasmodium Vivax Efficacy Trial in Cruzeiro do Sul, Acre, Brazil: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02043652).
- PLATINUM QCAIndependent statistical analysis of A Prospective, Multi-center Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element™): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04177810).
- Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies: primary endpoint results,…
- PNPIndependent statistical analysis of BlueWind Medical Reprieve System for the Treatment of PNP: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02062398).
- POLBOS-LMIndependent statistical analysis of POLish Bifurcation Optimal Treatment Strategy Study for Left Main Bifurcation Percutaneous Coronary Intervention (PCI): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Poly-ICLCIndependent statistical analysis of Enhancement by Poly-ICLC During HIV-1 Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02071095).
- Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.: Complete Statistical AnalysisIndependent statistical analysis of Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.: primary endpoint results, effect estimate with confidence…
- Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions: Complete Statistical AnalysisIndependent statistical analysis of Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Portico and Navitor India Clinical Trial: Complete Statistical AnalysisIndependent statistical analysis of Portico and Navitor India Clinical Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05171712).
- PORTICO-1Independent statistical analysis of 5 Year Observation of Patients With PORTICO Valves: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01802788).
- Post Marketing Study in Subjects Who Have Type 2 Diabetes Using the EndoBarrier™ Gastrointestinal Liner: Complete Statistical AnalysisIndependent statistical analysis of Post Marketing Study in Subjects Who Have Type 2 Diabetes Using the EndoBarrier™ Gastrointestinal Liner: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Post-authorization Safety Study in Type 2 Diabetic Patients in Saudi Arabia Treated With Empagliflozin to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion, and Dehydration: Complete Statistical AnalysisIndependent statistical analysis of Post-authorization Safety Study in Type 2 Diabetic Patients in Saudi Arabia Treated With Empagliflozin to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion,…
- Post-operative Radiation With Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck: Complete Statistical AnalysisIndependent statistical analysis of Post-operative Radiation With Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis: Complete Statistical AnalysisIndependent statistical analysis of Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Postmarketing Immunogenicity Study in HAE Subjects Treated With Berinert: Complete Statistical AnalysisIndependent statistical analysis of Postmarketing Immunogenicity Study in HAE Subjects Treated With Berinert: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01467947).
- Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Postplacental Mirena IUD Insertion and Estimating Expulsion Rates.: Complete Statistical AnalysisIndependent statistical analysis of Postplacental Mirena IUD Insertion and Estimating Expulsion Rates.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01230242).
- POTENTE Study: A Study of Early Virological Response in Naive Patients With Chronic Hepatitis C, Genotype 2 or 3, Treated With PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin).: Complete Statistical AnalysisIndependent statistical analysis of POTENTE Study: A Study of Early Virological Response in Naive Patients With Chronic Hepatitis C, Genotype 2 or 3, Treated With PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin).:…
- POWERIndependent statistical analysis of Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…